Clinical trials: Locally Advanced Lung Carcinoma
Non-Small-Cell Lung Carcinoma
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
This is a Phase II, non-randomized, open label study of ILX651 in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC).
- Trial name
- NCT00078455
- Testing
- ILX651
- Where
- 10 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or…
- Trial name
- NCT07680790
- Testing
- Iza-bren, Osimertinib, Pemetrexed
- Where
- 204 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer (NSCLC)
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
The primary scientific question of interest is whether the addition of ociperlimab to platinum-based chemotherapy and tislelizumab improve progression-free survival (PFS) or overall survival (OS) compared to pembrolizumab and…
- Trial name
- AdvanTIG-306 (NCT05791097)
- Testing
- Ociperlimab, Tislelizumab, Pembrolizumab
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer
- Trial name
- NCT06883630
- Testing
- RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148
- Where
- 24 sites in China
- Volunteers
- 121 people
- Sponsor
- RemeGen Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally…
- Trial name
- NCT04832854
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- SANOVO (NCT05009836)
- Testing
- Savolitinib, Osimertinib
- Where
- China
- Volunteers
- 412 people
- Sponsor
- Hutchmed
Carcinoma, Non-Small-Cell Lung
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
- Trial name
- REVEAL (NCT03761901)
- Testing
- 1L treatment, 2L Treatment, 3L treatment
- Where
- 15 sites in Belgium
- Volunteers
- 141 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX301…
- Trial name
- NCT05102214
- Testing
- HLX301
- Where
- 5 sites in Australia
- Volunteers
- 150 people
- Sponsor
- Shanghai Henlius Biotech
NSCLC, EGFR Activating Mutation
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
- Trial name
- NCT05382728
- Testing
- TY-9591, Osimertinib
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- TYK Medicines, Inc
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Non-Squamous Non-small Cell Lung Cancer
Phase III Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer…
- Trial name
- NCT06396065
- Testing
- AK112 Injection
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 420 people
- Sponsor
- Summit Therapeutics
Non-Small Cell Lung Cancer
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung…
- Trial name
- NCT02544633
- Testing
- MGCD265
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- Mirati Therapeutics Inc.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
This open-label, non-randomized, one-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show…
- Trial name
- NCT01609543
- Testing
- erlotinib [Tarceva]
- Where
- 23 sites in Hungary, Latvia and 1 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Study of DF6002 Alone and in Combination With Nivolumab
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
- Trial name
- NCT04423029
- Testing
- DF6002, Nivolumab
- Where
- 32 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Dragonfly Therapeutics
Non Small Cell Lung Cancer
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
- Trial name
- NCT04395677
- Testing
- AB-106
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Nuvation Bio Inc.
Non-Small Cell Lung Cancer
A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer
The purposes of this study are to determine: the safety of pemetrexed and any side effects that might be associated with it how much pemetrexed should be given to patients.
- Trial name
- NCT00078260
- Testing
- pemetrexed
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 589 people
- Sponsor
- Eli Lilly and Company
Non-small Lung Cancer
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
The aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities.
- Trial name
- NCT07308106
- Testing
- SKB571 for injection
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants…
- Trial name
- DESTINY-Lung06 (NCT06899126)
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed
- Where
- 246 sites in United States, Argentina and 22 more
- Volunteers
- 686 people
- Sponsor
- Daiichi Sankyo
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Trial name
- NCT05607550
- Testing
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 398 people
- Sponsor
- ArriVent BioPharma, Inc.